Schizophrenia Research
Volume 67, Issue 1 , Pages 41-52 , 1 March 2004

Microarray screening of lymphocyte gene expression differences in a multiplex schizophrenia pedigree

Received 13 January 2003 ,Revised 15 April 2003 ,Accepted 22 April 2003.

References 

  1. Ammar DA, Eadie DM, Wong DJ, Ma YY, Kolakowski LF, Yang-Feng TL, et al. Characterization of the human type 2 neuropeptide Y receptor gene (NPY2R) and localization to the chromosome 4q region containing the type 1 neuropeptide Y receptor gene. Genomics. 1996;38:392–398
  2. Baldi P, Long AD. A Bayesian framework for the analysis of microarray expression data: regularized t-test and statistical inferences of gene changes. Bioinformatics. 2001;17:509–519
  3. Baron M. Genetics of schizophrenia and the new millennium: progress and pitfalls. Am. J. Hum. Genet. 2001;68:299–312
  4. Barrett T, Cheadle C, Wood WB, Teichberg D, Donovan DM, Freed WJ, et al. Assembly and use of a broadly applicable neural cDNA microarray. Restor. Neurol. Neurosci. 2001;18:127–135
  5. Breen G, Fox H, Glen I, Collier D, Shaw D, St. Clair D. Association study of the CACN1A4 (SCA6) triplet repeat and schizophrenia. Psychiatr. Genet. 1999;9:111–113
  6. Caberlotto L, Hurd YL. Neuropeptide Y Y(1) and Y(2) receptor mRNA expression in the prefrontal cortex of psychiatric subjects. Relationship of Y(2) subtype to suicidal behavior. Neuropsychopharmacology. 2001;25:91–97
  7. Cardno AG, Holmans PA, Rees MI, Jones LA, McCarthy GM, Hamshere ML, et al. A genomewide linkage study of age at onset in schizophrenia. Am. J. Med. Genet. 2001;105:439–445
  8. Coon H, Myles-Worsley M, Tiobech J, Hoff M, Rosenthal J, Bennett P, et al. Evidence for a chromosome 2p13–14 schizophrenia susceptibility locus in families from Palau, Micronesia. Mol. Psychiatry. 1998;3:521–527
  9. DeLisi LE, Mesen A, Rodriguez C, Bertheau A, LaPrade B, Llach M, et al. Genome-wide scan for linkage to schizophrenia in a Spanish-origin cohort from Costa Rica. Am. J. Med. Genet. 2002;114:497–508
  10. Frederiksen SO, Ekman R, Gottfries CG, Widerlov E, Jonsson S. Reduced concentrations of galanin, arginine vasopressin, neuropeptide Y and peptide YY in the temporal cortex but not in the hypothalamus of brains from schizophrenics. Acta Psychiatr. Scand. 1991;83:273–277
  11. Freed WJ, Vawter MP. Microarrays: applications in neuroscience to disease, development, and repair. Restor. Neurol. Neurosci. 2001;18:53–56
  12. Gabriel SM, Davidson M, Haroutunian V, Powchik P, Bierer LM, Purohit DP, et al. Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex. Biol. Psychiatry. 1996;39:82–91
  13. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2001;98:4746–4751
  14. Hemby SE, Ginsberg SD, Brunk B, Arnold SE, Trojanowski JQ, Eberwine JH. Gene expression profile for schizophrenia: discrete neuron transcription patterns in the entorhinal cortex. Arch. Gen. Psychiatry. 2002;59:631–640
  15. Herzog H, Darby K, Ball H, Hort Y, Beck-Sickinger A, Shine J. Overlapping gene structure of the human neuropeptide Y receptor subtypes Y1 and Y5 suggests coordinate transcriptional regulation. Genomics. 1997;41:315–319
  16. Hovatta I, Varilo T, Suvisaari J, Terwilliger JD, Ollikainen V, Arajarvi R, et al. A genomewide screen for schizophrenia genes in an isolated Finnish subpopulation, suggesting multiple susceptibility loci. Am. J. Hum. Genet. 1999;65:1114–1124
  17. Ilani T, Ben-Shachar D, Strous RD, Mazor M, Sheinkman A, Kotler M, et al. A peripheral marker for schizophrenia: increased levels of D3 dopamine receptor mRNA in blood lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 2001;98:625–628
  18. Iritani S, Kuroki N, Niizato K, Ikeda K. Morphological changes in neuropeptide Y-positive fiber in the hippocampal formation of schizophrenics. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2000;24:241–249
  19. Kanzig S. A peripheral marker for schizophrenia: increased levels of D3-receptor-mRNA in blood lymphocytes. Psychiatr. Prax. 2001;28:251–252
  20. Kuromitsu J, Yokoi A, Kawai T, Nagasu T, Aizawa T, Haga S, et al. Reduced neuropeptide Y mRNA levels in the frontal cortex of people with schizophrenia and bipolar disorder. Gene Expr. Patterns. 2001;1:17–21
  21. Kwak YT, Koo MS, Choi CH, Sunwoo I. Change of dopamine receptor mRNA expression in lymphocyte of schizophrenic patients. BMC Med. Genet. 2001;2:3
  22. Lehrmann E, Oyler J, Vawter MP, Hyde TM, Kolachana B, Kleinman JE, et al. Transcriptional profiling in the human prefrontal cortex: evidence for two activational states associated with cocaine abuse. Pharmacogenomics J. 2003;3:27–40
  23. Long AD, Mangalam HJ, Chan BY, Tolleri L, Hatfield GW, Baldi P. Improved statistical inference from DNA microarray data using analysis of variance and a Bayesian statistical framework. Analysis of global gene expression in Escherichia coli K12. J. Biol. Chem. 2001;276:19937–19944
  24. Lutz CM, Frankel WN, Richards JE, Thompson DA. Neuropeptide Y receptor genes on human chromosome 4q31–q32 map to conserved linkage groups on mouse chromosomes 3 and 8. Genomics. 1997;41:498–500
  25. Middleton FA, Mirnics K, Pierri JN, Lewis DA, Levitt P. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J. Neurosci. 2002;22:2718–2729
  26. Mimmack ML, Ryan M, Baba H, Navarro-Ruiz J, Iritani S, Faull RL, et al. Gene expression analysis in schizophrenia: reproducible up-regulation of several members of the apolipoprotein L family located in a high-susceptibility locus for schizophrenia on chromosome 22. Proc. Natl. Acad. Sci. U. S. A. 2002;99:4680–4685
  27. Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron. 2000;28:53–67
  28. Mowry BJ, Ewen KR, Nancarrow DJ, Lennon DP, Nertney DA, Jones HL, et al. Second stage of a genome scan of schizophrenia: study of five positive regions in an expanded sample. Am. J. Med. Genet. 2000;96:864–869
  29. Niculescu AB, Segal DS, Kuczenski R, Barrett T, Hauger RL, Kelsoe JR. Identifying a series of candidate genes for mania and psychosis: a convergent functional genomics approach. Physiol. Genomics. 2000;4:83–91
  30. Paunio T, Ekelund J, Varilo T, Parker A, Hovatta I, Turunen JA, et al. Genome-wide scan in a nationwide study sample of schizophrenia families in Finland reveals susceptibility loci on chromosomes 2q and 5q. Hum. Mol. Genet. 2001;10:3037–3048
  31. Peters J, Van Kammen DP, Gelernter J, Yao J, Shaw D. Neuropeptide Y-like immunoreactivity in schizophrenia. Relationships with clinical measures. Schizophr. Res. 1990;3:287–294
  32. Pulver AE, Mulle J, Nestadt G, Swartz KL, Blouin JL, Dombroski B, et al. Genetic heterogeneity in schizophrenia: stratification of genome scan data using co-segregating related phenotypes. Mol. Psychiatry. 2000;5:650–653
  33. Redrobe J, Dumont Y, Quirion R. Neuropeptide Y (NPY) and depression: from animal studies to the human condition. Life Sci. 2002;71:2921
  34. Schwab SG, Eckstein GN, Hallmayer J, Lerer B, Albus M, Borrmann M, et al. Evidence suggestive of a locus on chromosome 5q31 contributing to susceptibility for schizophrenia in German and Israeli families by multipoint affected sib-pair linkage analysis. Mol. Psychiatry. 1997;2:156–160
  35. Sternweis PC, Robishaw JD. Isolation of two proteins with high affinity for guanine nucleotides from membranes of bovine brain. J. Biol. Chem. 1984;259:13806–13813
  36. Straub RE, MacLean CJ, Ma Y, Webb BT, Myakishev MV, Harris-Kerr C, et al. Genome-wide scans of three independent sets of 90 Irish multiplex schizophrenia families and follow-up of selected regions in all families provides evidence for multiple susceptibility genes. Mol. Psychiatry. 2002;7:542–559
  37. Tani M, Mui K, Minami Y, Kiriike N. Association of a GTP-binding protein Go alpha subunit mutation with schizophrenia. Mol. Psychiatry. 2001;6:359
  38. Truckenmiller ME, Vawter MP, Zhang P, Conejero-Goldberg C, Dillon-Carter O, Morales N, et al. AF5, a CNS cell line immortalized with an N-terminal fragment of SV40 large T: growth, differentiation, genetic stability, and gene expression. Exp. Neurol. 2002;175(2):318–337
  39. Vawter MP, Barrett T, Cheadle C, Sokolov BP, Wood WH, Donovan DM, et al. Application of cDNA microarrays to examine gene expression differences in schizophrenia. Brain Res. Bull. 2001;55:641–650
  40. Vawter MP, Crook JM, Hyde TM, Kleinman JE, Weinberger DR, Becker KG, et al. Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study. Schizophr. Res. 2002;58:11–20
  41. Vawter MP, Weickert CS, Ferran E, Matsumoto M, Hyde TM, Kleinman JE, et al. Neuronal gene expression is decreased in prefrontal cortex in schizophrenia. Schizophr. Res. 2003;61(Suppl. 1):67
  42. Williams NM, O'Donovan MC, Owen MJ. Genome scans and microarrays: converging on genes for schizophrenia?. Genome Biol. 2002;3:1011.1–1011.5
  43. Yan WL, Guan XY, Green ED, Nicolson R, Yap TK, Zhang J, et al. Childhood-onset schizophrenia/autistic disorder and t(1;7) reciprocal translocation: identification of a BAC contig spanning the translocation breakpoint at 7q21. Am. J. Med. Genet. 2000;96:749–753

PII: S0920-9964(03)00151-8

doi: 10.1016/S0920-9964(03)00151-8

Schizophrenia Research
Volume 67, Issue 1 , Pages 41-52 , 1 March 2004

Article Tools

* Image Usage & Resolution